Evidence map›Paper›PMID 38996712›Full record

ArticleMultiple sclerosis and related disorders2024

Spinal cord size as promising biomarker of disability outcomes after hematopoietic stem cell transplantation in multiple sclerosis.

Alice Mariottini, Emily H Stack, Govind Nair, Chiara Nozzoli, Tianxia Wu, Leonardo Marchi, Riccardo Boncompagni, Anna Maria Repice, Enrico Fainardi, Francesca Di Pasquale and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis and related disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Alice MariottiniDepartment of Neurofarba, University of Florence, Florence, Italy; Department of Neurology 2 and Tuscan Region Multiple Sclerosis Referral Centre, Careggi University Hospital, Florence, Italy.
Emily H StackNational Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, 20892 USA.
Govind NairNational Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, 20892 USA.
Chiara NozzoliCell Therapy and Transfusion Medicine Unit, Careggi University Hospital, Florence, Italy.
Tianxia WuNational Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, 20892 USA.
Leonardo MarchiDepartment of Neurofarba, University of Florence, Florence, Italy.
Riccardo BoncompagniCell Therapy and Transfusion Medicine Unit, Careggi University Hospital, Florence, Italy.
Anna Maria RepiceDepartment of Neurology 2 and Tuscan Region Multiple Sclerosis Referral Centre, Careggi University Hospital, Florence, Italy.
Enrico FainardiNeuroradiology Unit, Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy; Neuroradiology Unit, Department of Radiology, Careggi University Hospital, Florence, Italy.
Francesca Di PasqualeDiagnostic Imaging Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
Edoardo CarlesiNeuroradiology Unit, Department of Radiology, Careggi University Hospital, Florence, Italy.
Riccardo SaccardiCell Therapy and Transfusion Medicine Unit, Careggi University Hospital, Florence, Italy.
Steven JacobsonNational Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, 20892 USA.
Luca MassacesiDepartment of Neurofarba, University of Florence, Florence, Italy; Department of Neurology 2 and Tuscan Region Multiple Sclerosis Referral Centre, Careggi University Hospital, Florence, Italy. Electronic address: massacesi@unifi.it.

Funding

NINDS Quantitative MRI Core FacilityZICNS009438 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI NAIR, GOVIND · 2022 to 2025
$4.3M
Intramural NIH HHS Z99 NS999999Intramural NIH HHS ZIC NS009438
6 · The paper itself

Abstract

backgroundBiomarkers predictive of disability outcomes in individual multiple sclerosis (MS) patients undergoing autologous haematopoietic stem cell transplantation (AHSCT) are currently lacking. As correlations between spinal cord atrophy and clinical disability in MS were previously described, in this study spinal cord size was investigated in MS patients treated with AHSCT, exploring whether baseline spinal cord volume may predict disability progression after AHSCT.

methodsrelapsing-remitting (RR-) and secondary-progressive (SP-) MS patients treated with AHSCT (BEAM/ATG regimen) at a single academic centre in Florence, who performed at least two standardized brain magnetic resonance imaging (MRIs) scans (acquired between one-year pre-AHSCT to 5 years after AHSCT) were included. Cervical spinal cord atrophy was estimated as upper cervical spinal cord cross-sectional area (SCCSA). Brain volume loss (BVL) was analysed at the same timepoints.

resultsEleven (8 RR-; 3 SP-) MS patients were included. Over a median follow-up of 66 (range 37 - 100) months, no relapses nor brain MRI activity were observed; disability progressed in 2 cases (both SP-MS). Baseline SCCSA was associated with EDSS change between pre- and one-year post-AHSCT. Compared to patients who stabilized, patients who progressed after AHSCT tended to have lower SCCSA at C4 level at baseline and year 1 after AHSCT. Longitudinal changes in SCCSA or BVL did not correlate with EDSS change.

conclusionsBaseline pre-AHSCT SCCSA, but not its longitudinal changes nor BVL, predicted EDSS change within the two years following AHSCT. SCCSA may represent a biomarker of treatment response and a promising screening tool for assessing patient eligibility for high-impact treatments such as AHSCT.

Indexed as

Hematopoietic Stem Cell TransplantationMagnetic Resonance ImagingMultiple Sclerosis, Relapsing-RemittingSpinal CordAdultAtrophyBiomarkersBrainDisease ProgressionFemaleFollow-Up StudiesHumansMaleMiddle AgedMultiple Sclerosis, Chronic ProgressiveBiomarkersAtrophyDisabilityhematopoietic stem cell transplantationMagnetic resonance imagingMultiple sclerosisSpinal cordTransplant

Identifiers

PMID38996712
PMCPMC13581127

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.